Skip to main content

Table 3 DAS28 (ESR) composite and individual component values, and SDAI and HAQ DI scores at 0.5, 1, 3 and 5 years of ADA exposure and last observation

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Parameter 0.5 Y 1 Y 3 Y 5 Y LO
DAS28 (ESR)      
 Mean (SD) 3.6 (1.5) 3.4 (1.4) 3.1 (1.3) 2.9 (1.2) 3.8 (1.6)
 Median (IQR) 3.5 (2.0) 3.3 (2.0) 2.9 (1.8) 2.8 (1.5) 3.6 (2.4)
PtGA, mm VAS      
 Mean (SD) 30.6 (24.6) 27.8 (23.7) 25.1 (22.9) 23.4 (21.6) 34.5 (27.1)
 Median (IQR) 25.0 (37.0) 22.0 (35.0) 19.0 (32.0) 18.0 (30.3) 30.0 (44.0)
TJC (28)      
 Mean (SD) 4.1 (5.4) 3.2 (4.6) 2.4 (4.1) 1.9 (3.6) 4.6 (6.3)
 Median (IQR) 2.0 (6.0) 2.0 (4.0) 1.0 (3.0) 0.0 (2.0) 2.0 (6.0)
SJC (28)      
 Mean (SD) 3.0 (4.1) 2.3 (3.5) 1.4 (2.8) 1.1 (2.5) 3.1 (4.6)
 Median (IQR) 2.0 (4.0) 1.0 (3.0) 0.0 (2.0) 0.0 (1.0) 1.0 (4.5)
ESR, mm/h      
 Mean (SD) 24.1 (20.0) 23.1 (19.3) 21.7 (17.5) 21.3 (17.3) 26.9 (22.2)
 Median (IQR) 18.0 (22.0) 18.0 (20.0) 17.0 (21.0) 17.0 (19.0) 20.0 (27.0)
SDAI      
 Mean (SD) 13.7 (12.1) 11.4 (10.6) 8.8 (9.0) 7.6 (8.2) 14.7 (14.2)
 Median (IQR) 10.3 (13.5) 8.5 (11.9) 6.1 (9.3) 5.2 (8.0) 10.1 (16.8)
HAQ DI score      
 Mean (SD) 1.01 (0.78) 0.94 (0.76) 0.85 (0.73) 0.80 (0.72) 1.09 (0.82)
 Median (IQR) 1.00 (1.3) 0.88 (1.3) 0.75 (1.1) 0.63 (1.1) 1.00 (1.4)
  1. ADA, adalimumab; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ DI, Health Assessment Questionnaire Disability Index; IQR, interquartile range; LO, last observation; PtGA, patient global assessment; SD, standard deviation; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.